Acute Myeloid Leukemia: Updates From The ASH 2022 Annual Meeting

Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.

Data from the following clinical trials are discussed:

  • 223: Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m ND-AML Treated with Ivo+AZA in the AGILE Study
  • 61: Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
  • 2746: Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
  • 2758: A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Supported in part by Amgen Oncology, Servier, and Takeda Oncology. Content developed independently by OncLive®.

Related Videos
Bradley W. Christensen, MD
Expert on urothelial carcinoma
Experts on urothelial carcinoma
Experts on BTC
Experts on BTC
Aaron Gerds, MD, an expert on myeloproliferative neoplasms
Expert on AML
Expert on AML
Sapna Patel, BA, MD
Experts on CRC